<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04825470</url>
  </required_header>
  <id_info>
    <org_study_id>TRANSGIST</org_study_id>
    <nct_id>NCT04825470</nct_id>
  </id_info>
  <brief_title>Liver Transplantation for Unresectable GIST Liver Metastases</brief_title>
  <acronym>TRANSGIST</acronym>
  <official_title>Liver Transplantation in Patients With Unresectable GastroIntestinal Stromal Tumors (GIST) Liver Metastases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitario Virgen de la Arrixaca</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Universitario Virgen de la Arrixaca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Liver Transplantation for Unresectable GIST Liver Metastases&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Through study completion, an average of 2 years</time_frame>
    <description>Survival</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Graft Survival</measure>
    <time_frame>Through study completion, an average of 2 years</time_frame>
    <description>Liver graft Survival</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Relapse free survival</measure>
    <time_frame>Through study completion, an average of 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease free survival</measure>
    <time_frame>Through study completion, an average of 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Liver Diseases</condition>
  <condition>Liver Cancer</condition>
  <condition>Liver Metastases</condition>
  <condition>Liver Neoplasms</condition>
  <condition>Liver Mass</condition>
  <condition>Liver Carcinoma</condition>
  <condition>Liver Transplant; Complications</condition>
  <condition>Liver Transplant Disorder</condition>
  <condition>GIST</condition>
  <condition>GIST, Malignant</condition>
  <condition>Gastrointestinal Stromal Tumors</condition>
  <condition>Gastrointestinal Stromal Tumor of Duodenum</condition>
  <condition>Gastrointestinal Stromal Tumor of Rectum</condition>
  <condition>Gastrointestinal Stromal Tumor of Other Sites</condition>
  <condition>Gastrointestinal Stromal Tumor, Unspecified Site</condition>
  <condition>Gastrointestinal Stromal Tumor of Stomach</condition>
  <condition>Gastrointestinal Stromal Tumor of Esophagus (Disorder)</condition>
  <condition>Gastrointestinal Stromal Tumor by AJCC V8 Stage</condition>
  <condition>Gastrointestinal Stromal Tumor, Malignant</condition>
  <condition>Gastrointestinal Stromal Tumor (GIST) of the Gastrointestinal Tract</condition>
  <condition>Gastrointestinal Stromal Tumor of Small Intestine (Disorder)</condition>
  <condition>Gastrointestinal Stromal Tumor of Large Intestine (Disorder)</condition>
  <condition>Metastases to Liver</condition>
  <condition>Metastatic Liver Cancer</condition>
  <condition>Metastasis</condition>
  <condition>Metastases</condition>
  <condition>Liver Transplantation</condition>
  <condition>Transplant Oncology</condition>
  <arm_group>
    <arm_group_label>Liver Transplantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Tyrosine kinase inhibitors therapy only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Liver Transplantation</intervention_name>
    <description>Liver Transplantation</description>
    <arm_group_label>Liver Transplantation</arm_group_label>
    <arm_group_label>Tyrosine kinase inhibitors therapy only</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  GIST diagnosis (c-Kit, CD34, DOG-1)&#xD;
&#xD;
          -  Imatinib-sensitive mutation&#xD;
&#xD;
          -  Non-resectable liver metastases&#xD;
&#xD;
          -  Abscence of extrahepatic disease&#xD;
&#xD;
          -  Period greater than two years between primary tumor and metastases diagnosis&#xD;
&#xD;
          -  Favorable tumor biology (low or intermediate risk)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 23, 2021</study_first_submitted>
  <study_first_submitted_qc>March 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 1, 2021</study_first_posted>
  <last_update_submitted>March 29, 2021</last_update_submitted>
  <last_update_submitted_qc>March 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Universitario Virgen de la Arrixaca</investigator_affiliation>
    <investigator_full_name>Felipe Alconchel</investigator_full_name>
    <investigator_title>MD, PhD, Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>liver transplantation</keyword>
  <keyword>gastrointestinal stromal tumor (GIST)</keyword>
  <keyword>Transplant Oncology</keyword>
  <keyword>liver neoplasms</keyword>
  <keyword>liver metastases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
    <mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

